Top

BMC Cancer

Published in:

01-12-2021 | Gastric Cancer | Research

LncRNA LINC00342 promotes gastric cancer progression by targeting the miR-545-5p/CNPY2 axis

Authors: Run Liu, Xianwu Yang

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

This study aimed to explore the role and underlying molecular mechanisms of long non-coding RNA (lncRNA) LINC00342 in gastric cancer (GC).

Methods

The expression of LINC00342 in GC tissues was evaluated by Quantitative reverse transcription polymerase chain reaction (qRT-PCR). Silencing of LINC00342 was conducted to investigate the effect of LINC00342 in vitro and in vivo. The underlying molecular mechanisms of LINC00342 were determined by dual luciferase reporter assay, Western blotting analysis and rescue experiments. Biological functions of LINC00342 were evaluated by cell counting kit-8 (CCK-8) assay, colony formation assay, wound healing assay and Transwell assays. In addition, a tumor model was used to verify the effect of LINC00342 in tumorigenesis in vivo.

Results

LINC00342 was significantly upregulated in GC tissues and cell lines. Silencing of LINC00342 efficiently inhibited proliferation, migration and invasion of AGS cells in vitro, and also suppressed the tumorigenesis of GC in vivo. Functional experiments showed that LINC00342 regulated the expression of canopy fibroblast growth factor signaling regulator 2 (CNPY2) by competitively sponging miR-545-5p. Rescue experiments showed that inhibition of miR-545-5p and overexpression of CNPY2 significantly reversed cell phenotypes caused by silencing of LINC00342.

Conclusion

LINC00342 plays a potential oncogenic role in GC by targeting the miR545-5p/CNPY2 axis, and might act as a novel therapeutic target for GC.

Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635–48.CrossRefPubMed

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. https://doi.org/10.3322/caac.21262.CrossRefPubMed

Li R, Liu B, Gao J. The application of nanoparticles in diagnosis and theranostics of gastric cancer. Cancer Lett. 2017;386:123–30. https://doi.org/10.1016/j.canlet.2016.10.032.CrossRefPubMed

Zhang JX, Xu Y, Gao Y, Chen C, Zheng ZS, Yun M, et al. Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway. Mol Cancer. 2017;16(1):18. https://doi.org/10.1186/s12943-017-0586-y.CrossRefPubMedPubMedCentral

Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and Cancer: a new paradigm. Cancer Res. 2017;77(15):3965–81. https://doi.org/10.1158/0008-5472.CAN-16-2634.CrossRefPubMedPubMedCentral

Malakar P, Shilo A, Mogilevsky A, Stein I, Pikarsky E, Nevo Y, et al. Long noncoding RNA MALAT1 promotes hepatocellular carcinoma development by SRSF1 upregulation and mTOR activation. Cancer Res. 2017;77(5):1155–67. https://doi.org/10.1158/0008-5472.CAN-16-1508.CrossRefPubMed

Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing MiRNA-LncRNA Interactions. Methods Mol Biol. 2016;1402:271–86.CrossRefPubMed

Nachtergaele S, He C. The emerging biology of RNA post-transcriptional modifications. RNA Biol. 2017;14(2):156–63. https://doi.org/10.1080/15476286.2016.1267096.CrossRefPubMed

Wang L, Chen Z, An L, Wang Y, Zhang Z, Guo Y, et al. Analysis of long non-coding RNA expression profiles in non-small cell lung Cancer. Cell Physiol Biochem. 2016;38(6):2389–400. https://doi.org/10.1159/000445591.CrossRefPubMed

10.

Chen QF, Kong JL, Zou SC, Gao H, Wang F, Qin SM, et al. LncRNA LINC00342 regulated cell growth and metastasis in non-small cell lung cancer via targeting miR-203a-3p. Eur Rev Med Pharmacol Sci. 2019;23(17):7408–18. https://doi.org/10.26355/eurrev_201909_18849.CrossRefPubMed

11.

Liu Z, Kang Z, Dai Y, Zheng H, Wang Y. Long noncoding RNA LINC00342 promotes growth of infantile hemangioma by sponging miR-3619-5p from HDGF. Am J Phys Heart Circ Phys. 2019;317(4):H830–h839. https://doi.org/10.1152/ajpheart.00188.2019.CrossRef

12.

Miao Z, Liu S, Xiao X, Li D. LINC00342 regulates cell proliferation, apoptosis, migration and invasion in colon adenocarcinoma via miR-545-5p/MDM2 axis. Gene. 2020;743:144604. https://doi.org/10.1016/j.gene.2020.144604.CrossRefPubMed

13.

Huang Y, Zhang J, Hou L, Wang G, Liu H, Zhang R, et al. LncRNA AK023391 promotes tumorigenesis and invasion of gastric cancer through activation of the PI3K/Akt signaling pathway. J Exp Clin Cancer Res. 2017;36(1):194. https://doi.org/10.1186/s13046-017-0666-2.CrossRefPubMedPubMedCentral

14.

Luo X, He Y, Tang H, Cao Y, Gao M, Liu B, et al. Effects of HER2 on the invasion and migration of gastric cancer. Am J Transl Res. 2019;11(12):7604–13.PubMedPubMedCentral

15.

Kumar JD, Aolymat I, Tiszlavicz L, Reisz Z, Garalla HM, Beynon R, et al. Chemerin acts via CMKLR1 and GPR1 to stimulate migration and invasion of gastric cancer cells: putative role of decreased TIMP-1 and TIMP-2. Oncotarget. 2019;10(2):98–112. https://doi.org/10.18632/oncotarget.26414.CrossRefPubMedPubMedCentral

16.

Wang S, Wu S, Zhu H, Ding B, Cai Y, Ni J, et al. PSCA rs2294008 polymorphism contributes to the decreased risk for cervical cancer in a Chinese population. Sci Rep. 2016;6(1):23465. https://doi.org/10.1038/srep23465.CrossRefPubMedPubMedCentral

17.

Zhang X, Zhang W, Jiang Y, Liu K, Ran L, Song F. Identification of functional lncRNAs in gastric cancer by integrative analysis of GEO and TCGA data. J Cell Biochem. 2019;120(10):17898–911. https://doi.org/10.1002/jcb.29058.CrossRefPubMed

18.

Liu Z, Chen Z, Fan R, Jiang B, Chen X, Chen Q, et al. Over-expressed long noncoding RNA HOXA11-AS promotes cell cycle progression and metastasis in gastric cancer. Mol Cancer. 2017;16(1):82. https://doi.org/10.1186/s12943-017-0651-6.CrossRefPubMedPubMedCentral

19.

Zhang C, Ma MH, Liang Y, Wu KZ, Dai DQ. Novel long non-coding RNA LINC02532 promotes gastric cancer cell proliferation, migration, and invasion in vitro. World J Gastrointestin Oncol. 2019;11(2):91–101. https://doi.org/10.4251/wjgo.v11.i2.91.CrossRef

20.

Dykes IM, Emanueli C. Transcriptional and post-transcriptional gene regulation by long non-coding RNA. Genomics Proteomics Bioinformatics. 2017;15(3):177–86. https://doi.org/10.1016/j.gpb.2016.12.005.CrossRefPubMedPubMedCentral

21.

Zhang HL, Du XY, Dong QR. LncRNA XIXT promotes osteogenic differentiation of bone mesenchymal stem cells and alleviates osteoporosis progression by targeting miRNA-30a-5p. Eur Rev Med Pharmacol Sci. 2019;23(20):8721–9. https://doi.org/10.26355/eurrev_201910_19266.CrossRefPubMed

22.

Shi X, You X, Zeng WC, Deng YJ, Hong HL, Huang OX, et al. LncRNA PAPAS aggravates the progression of gastric cancer through regulating miRNA-188-5p. Eur Rev Med Pharmacol Sci. 2019;23(24):10761–8. https://doi.org/10.26355/eurrev_201912_19778.CrossRefPubMed

23.

Zhang L, Kang W, Lu X, Ma S, Dong L, Zou B. LncRNA CASC11 promoted gastric cancer cell proliferation, migration and invasion in vitro by regulating cell cycle pathway. Cell Cycle. 2018;17(15):1886–900.CrossRefPubMedPubMedCentral

24.

Taniguchi H, Ito S, Ueda T, Morioka Y, Kayukawa N, Ueno A, et al. CNPY2 promoted the proliferation of renal cell carcinoma cells and increased the expression of TP53. Biochem Biophys Res Commun. 2017;485(2):267–71. https://doi.org/10.1016/j.bbrc.2017.02.095.CrossRefPubMed

25.

Yan P, Gong H, Zhai X, Feng Y, Wu J, He S, et al. Decreasing CNPY2 expression diminishes colorectal tumor growth and development through activation of p53 pathway. Am J Pathol. 2016;186(4):1015–24. https://doi.org/10.1016/j.ajpath.2015.11.012.CrossRefPubMed

26.

Dou Y, Lei JQ, Guo SL, Zhao D, Yue HM, Yu Q. The CNPY2 enhances epithelial-mesenchymal transition via activating the AKT/GSK3β pathway in non-small cell lung cancer. Cell Biol Int. 2018;42(8):959–64. https://doi.org/10.1002/cbin.10961.CrossRefPubMed

27.

Wang H, Kanmangne D, Li R, Qian Z, Xia X, Wang X, et al. miR-30a-3p suppresses the proliferation and migration of lung adenocarcinoma cells by downregulating CNPY2. Oncol Rep. 2020;43(2):646–54. https://doi.org/10.3892/or.2019.7423.CrossRefPubMed

28.

Yu D, Qin Y, Jun-Qiang L, Shun-Lin G. CNPY2 enhances resistance to apoptosis induced by cisplatin via activation of NF-κB pathway in human non-small cell lung cancer. Biomed Pharmacother. 2018;103:1658–63.CrossRefPubMed

29.

Cui Y, Wang Y, Liu G. Protective effect of Barbaloin in a rat model of myocardial ischemia reperfusion injury through the regulation of the CNPY2-PERK pathway. Int J Mol Med. 2019;43(5):2015–23. https://doi.org/10.3892/ijmm.2019.4123.CrossRefPubMedPubMedCentral

30.

Wei GH, Wang X. lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21(17):3850–6.PubMed

31.

Hou X, Zhang Y, Qiao H. CCL18 promotes the invasion and migration of gastric cancer cells via ERK1/2/NF-κB signaling pathway. Tumour Biol. 2016;37(1):641–51. https://doi.org/10.1007/s13277-015-3825-0.CrossRefPubMed

32.

Poh AR, O'Donoghue RJ, Ernst M, Putoczki TL. Mouse models for gastric cancer: matching models to biological questions. J Gastroenterol Hepatol. 2016;31(7):1257–72. https://doi.org/10.1111/jgh.13297.CrossRefPubMedPubMedCentral

33.

Oh BY, Hong HK, Lee WY, Cho YB. Animal models of colorectal cancer with liver metastasis. Cancer Lett. 2017;387:114–20. https://doi.org/10.1016/j.canlet.2016.01.048.CrossRefPubMed

34.

Ghafouri-Fard S, Shoorei H, Taheri M. Non-coding RNAs are involved in the response to oxidative stress. Biomed Pharmacother. 2020;127:110228. https://doi.org/10.1016/j.biopha.2020.110228.CrossRefPubMed

35.

Ghafouri-Fard S, Abak A, Fattahi F, Hussen BM, Bahroudi Z, Shoorei H, et al. The interaction between miRNAs/lncRNAs and nuclear factor-κB (NF-κB) in human disorders. Biomed Pharmacother. 2021;138:111519. https://doi.org/10.1016/j.biopha.2021.111519.CrossRefPubMed

36.

Safa A, Abak A, Shoorei H, Taheri M, Ghafouri-Fard S. MicroRNAs as regulators of ERK/MAPK pathway: a comprehensive review. Biomed Pharmacother. 2020;132:110853. https://doi.org/10.1016/j.biopha.2020.110853.CrossRefPubMed

Title: LncRNA LINC00342 promotes gastric cancer progression by targeting the miR-545-5p/CNPY2 axis
Authors: Run Liu
Xianwu Yang
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Gastric Cancer
Gastric Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08829-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy

Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center

Hypofractionated radiotherapy in ten fractions for postmastectomy patients: a phase II study compared with another hypofractionation schedule with sixteen fractions

ABO genotypes and the risk of esophageal and gastric cancers

Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations

Discrepancy in p16 expression in patients with HPV-associated head and neck squamous cell carcinoma in Thailand: clinical characteristics and survival outcomes

Keynote webinar | Spotlight on antibody–drug conjugates in cancer